Celldex Therapeutics reported $714.56M in Operating Expenses for its fiscal quarter ending in June of 2026.





Operating Expenses Change Date
AbbVie USD 10.27B 1000K Jun/2026
Agenus USD -199.08M 22.15M Jun/2026
Amgen USD 11.69B 6.9B Jun/2026
Bristol-Myers Squibb USD 22.32B 2.25B Jun/2026
Celldex Therapeutics USD 714.56M 258.34M Jun/2026
Glaxosmithkline GBP 5.34B 3.83B Mar/2026
Nektar Therapeutics USD 49.12M 8.22M Mar/2026
Northwest Biotherapeutics USD 11.39M 120.04M Mar/2026
Pfizer USD 85.19B 4.91B Jun/2026
Rigel Pharmaceuticals USD 117.61M 35.67M Sep/2025
Roche Holding CHF 18.9B 2.12B Jun/2026